财务数据显示，从2021年到2023年，该公司的营业收入分别为4.66亿元、5.49亿元和5.73亿元。尽管营收稳步上行，但期内仍持续亏损。今年一季度，太美医疗的营收为1.32亿元，净亏损为1.18亿元。三年时间累计亏损已超12亿元。TaiMei Medical Technology (02576) has dropped by over 11% again. Since its listing on October 8, the stock has been in a downward trend for 5 trading days, and the current stock price has almost halved compared to the IPO price of 13 Hong Kong dollars.
According to the Wise Finance APP, TaiMei Medical Technology (02576) has dropped by over 11% again. Since its listing on October 8, the stock has been in a downward trend for 5 trading days, and the current stock price is down 11.23%, at 6.64 Hong Kong dollars, with a trading volume of 55.764 million Hong Kong dollars.
It is reported that Tai Mei Medical Technology is a digital solutions provider focusing on the pharmaceutical and medical instruments industry in China, designing and providing industry-specific software and digital services to aid in pharmaceutical and medical instrument research and marketing. According to WiseInsight Consulting, in 2023 based on revenue, Tai Mei Medical Technology is the largest digital solutions provider in China's pharmaceutical and medical instruments research and marketing field, with a market share of 5.9%.
Financial data shows that from 2021 to 2023, the company's revenue was 466 million yuan, 549 million yuan, and 5.73 billion yuan respectively. Despite the steady increase in revenue, the company has continued to operate at a loss. In the first quarter of this year, TaiMei Medical's revenue was 132 million yuan, with a net loss of 118 million yuan. The accumulated losses over the three years have exceeded 1.2 billion yuan.
